

*Contact Person:* Lawrence Ka-Yun Ng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6152, MSC 7804, Bethesda, MD 20892, 301-435-1719, [ngkl@csr.nih.gov](mailto:ngkl@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel Member Conflict: Vascular Biology and Hematology.

*Date:* November 29, 2023.

*Time:* 9:00 a.m. to 8:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Courtney Elaine Watkins, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496-3093, [courtney.watkins2@nih.gov](mailto:courtney.watkins2@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel Member Conflict: Hematology and Vascular Pathophysiology.

*Date:* November 29, 2023.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Ai-Ping Zou, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118, Bethesda, MD 20892, (301) 408-9497, [zouai@csr.nih.gov](mailto:zouai@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel Fellowships: Physiology and Pathobiology of Cardiovascular and Respiratory Systems.

*Date:* November 30–December 1, 2023.

*Time:* 9:00 a.m. to 7:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Kimm Hamann, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4118A, MSC 7814, Bethesda, MD 20892, 301-435-5575, [hamannkj@csr.nih.gov](mailto:hamannkj@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel Member Conflict: Topics in Bacterial Virulence and Bacterial-Host Interactions.

*Date:* November 30, 2023.

*Time:* 1:30 p.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Liying Guo, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4198, MSC 7812, Bethesda, MD 20892, (301) 827-7728, [lguo@mail.nih.gov](mailto:lguo@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine;

93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

*Dated:* September 28, 2023.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023-21888 Filed 10-3-23; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Tribal Opioid Response (TOR) Consultation

**AGENCY:** Substance Abuse and Mental Health Services Administration (SAMHSA), HHS.

**ACTION:** Notice of meeting and request for testimony.

**SUMMARY:** SAMHSA announces a Tribal Consultation Session on the Tribal Opioid Response (TOR) grant funding methodology. SAMHSA will host American Indian and Alaska Native (AI/AN) Federally Recognized Tribes for a virtual Tribal consultation session.

**DATES:** The Tribal consultation will be held on November 9th, at 2 p.m. ET.

SAMHSA will accept written Tribal testimony until 5 p.m., November 23rd, 2023.

**ADDRESSES:** Written tribal testimony should be submitted by email to [otap@samhsa.hhs.gov](mailto:otap@samhsa.hhs.gov). All submissions must include Tribal affiliation. All relevant comments, including any personal information provided, will be posted without change.

#### FOR FURTHER INFORMATION CONTACT:

Karen Hearod, MSW, LCSW, Director, Office of Tribal Affairs and Policy, Substance Abuse and Mental Health Services Administration, Telephone: 202-868-9931, Email: [otap@samhsa.hhs.gov](mailto:otap@samhsa.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Federally Recognized Indian Tribes represented by the Tribal President, Tribal Chair, or Tribal Governor, or an elected or appointed Tribal Leader, or their authorized representative(s) may participate in this consultation by submitting written views, opinions, recommendations, and data. Testimony received, including attachments and other supporting materials, are part of the public record and subject to public disclosure. Do not include any information in your testimony or supporting materials considered confidential or inappropriate for public

disclosure. If you include your name, contact information, or other personal identifiers in the body of your testimony, that information will be on public display. SAMHSA will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/near duplicate examples of a mass-mail campaign. SAMHSA will carefully consider all testimony submitted into the docket.

**Oral Tribal Testimony:** Based on the number of participants giving testimony and the time available, it may be necessary to limit speaking times for each presenter. We will adjourn the Tribal consultation meeting early if all attendees who requested to provide oral testimony in advance of and during the consultation have delivered their testimony.

**Written Tribal Testimony:** Written testimony will be accepted per the instructions provided in the **ADDRESSES** section above. Written testimony received in advance of the meeting will be included in the official record of the meeting. The consultation meeting will be recorded, transcribed, and posted without change to <https://www.samhsa.gov/tribal-affairs/news-events>, including any personal information provided.

This meeting is being held in accordance with Presidential Executive Order No. 13175, November 6, 2000, and Presidential Memorandums of November 5, 2009, and September 23, 2004, and January 26, 2021 on Consultation and Coordination with Indian Tribal Government and SAMHSA's Tribal Consultation Policy, which can be found at: [https://www.samhsa.gov/sites/default/files/topics/tribal\\_affairs/tribal-consultation-policy-2017.pdf](https://www.samhsa.gov/sites/default/files/topics/tribal_affairs/tribal-consultation-policy-2017.pdf).

**Purpose:** The purpose of this Consultation meeting is to advance SAMHSA support for, and collaboration with, federally recognized American Indian and Alaska Native (AI/AN) Tribes. To advance these goals, SAMHSA conducts government-to-government consultations with Indian Tribes represented by the Tribal President, Tribal Chair, or Tribal Governor, or an elected or appointed Tribal Leader, or their authorized representative(s) to the extent practicable and permitted by law before SAMHSA takes any action that will significantly affect Indian Tribes. Consultation is an enhanced form of communication that emphasizes trust, respect, and shared responsibility. It is an open and free exchange of

information and opinion among parties that leads to mutual understanding.

*Matters To Be Considered:*

The Tribal Opioid Response Program was first authorized in 2018 along with the State Opioid Response Program (SOR) under Title II Division H of the Consolidated Appropriations Act, 2018. This announcement addressed Healthy People 2020, Substance Abuse Topic Area HP 2020–SA. All grants and sub-awards made under this announcement were governed by 45 CFR part 75.

The purpose of the TOR program is to assist in addressing the overdose crisis in Tribal communities by increasing access to treatment of opioid use disorder (MOUD), and supporting the continuum of prevention, harm reduction, treatment, and recovery support services for opioid use disorder (OUD) and co-occurring substance use disorders.

The TOR program also supports the full continuum of prevention, harm reduction, treatment and recovery support services for stimulant misuse and use disorders, including for cocaine and methamphetamine. The TOR program emphasizes the use of medication-assisted treatment using one of the three FDA-approved medications for OUDs.

The TOR program encourages the use of traditional practices. Funding is for a two-year time frame. Since inception the TOR program has been funded using the user population estimates distributed by the Indian Health Services (IHS). SAMHSA is interested in receiving feedback and suggestions for alternate funding methodologies for the TOR program, including the questions below.

Should SAMHSA continue to use the IHS user population estimates as the basis for determining TOR grant award amounts? If so, what tiers of funding should be established?

Should SAMHSA award each TOR grant recipient the same amount, similar to other SAMHSA discretionary Tribal grant programs?

Should SAMHSA award funds based on proposed number of clients served using grant funding?

Should SAMHSA award funds based on proposed activities that will be funded through the grant?

Should SAMHSA use some combination of the above methodologies?

What other methodologies should be considered instead?

*Meeting Information:* Zoom Virtual Tribal Consultation. If you wish to attend the virtual consultation session, please register here: <https://www.zoomgov.com/meeting/register/>

*vJltdu6qpzsoH6xCvLz  
SWzOWOK3ENOV2iWQ.*

Instructions to access the Zoom virtual consultation will be provided in the link following registration. All elected Tribal officials are encouraged to submit written Tribal testimony by email.

Dated: September 28, 2023.

**Carlos Castillo,**

*Committee Management Officer.*

[FR Doc. 2023–21967 Filed 10–3–23; 8:45 am]

**BILLING CODE 4162–20–P**

## DEPARTMENT OF HOMELAND SECURITY

[Docket ID FEMA–2014–0022]

### Technical Mapping Advisory Council; Meeting

**AGENCY:** Federal Emergency Management Agency, Department of Homeland Security.

**ACTION:** Notice of Open Federal Advisory Committee Meeting.

**SUMMARY:** The Federal Emergency Management Agency (FEMA) Technical Mapping Advisory Council (TMAC) will hold a virtual public meeting on Friday, Oct. 27, 2023. The meeting will be open to the public via a Microsoft Teams Video Communications link.

**DATES:** The TMAC will meet on Friday, Oct. 27, 2023, from 8 a.m. to 5 p.m. Eastern Standard Time (EST). Please note that the meeting will close early if the TMAC has completed its business.

**ADDRESSES:** The meeting will be held virtually using the following Microsoft Teams Video Communications link (<https://tinyurl.com/5cdwv54e>).

Members of the public who wish to attend the in-person or virtual meeting must register in advance by sending an email to [FEMA-TMAC@fema.dhs.gov](mailto:FEMA-TMAC@fema.dhs.gov) (Attn: Brian Koper) by 5 p.m. EST on Wednesday, Oct. 18, 2023.

To facilitate public participation, members of the public are invited to provide written comments on the issues to be considered by the TMAC, as listed in the **SUPPLEMENTARY INFORMATION** caption below. Associated meeting materials will be available upon request after Wednesday, Oct. 18, 2023. To receive a copy of any relevant materials, please send the request to: [FEMA-TMAC@fema.dhs.gov](mailto:FEMA-TMAC@fema.dhs.gov) (Attn: Brian Koper). Written comments to be considered by the committee at the time of the meeting must be submitted and received by Friday, Oct. 20, 2023, 5 p.m. EST, identified by Docket ID FEMA–2014–0022, and submitted by one of the following methods:

- *Federal eRulemaking Portal:* <http://www.regulations.gov>. Follow the instructions for submitting comments.

- *Email:* Address the email TO: [FEMA-TMAC@fema.dhs.gov](mailto:FEMA-TMAC@fema.dhs.gov). Include the docket number in the subject line of the message. Include name and contact information in the body of the email.

*Instructions:* All submissions received must include the words “Federal Emergency Management Agency” and the docket number for this action. Comments received will be posted without alteration at <http://www.regulations.gov>, including any personal information provided. You may wish to review the Privacy & Security Notice via a link on the homepage of [www.regulations.gov](http://www.regulations.gov).

*Docket:* For docket access to read background documents or comments received by the TMAC, go to <http://www.regulations.gov> and search for the Docket ID FEMA–2014–0022.

A public comment period will be held on Friday, Oct. 27, 2023, from noon to 12:30 p.m. EST. The public comment period will not exceed 30 minutes. Please note that the public comment period may end before the time indicated, following the last call for comments. Contact the individual listed below to register as a speaker by Wednesday, Oct. 18, 2023, 5 p.m. EST. Please be prepared to submit a written version of your public comment.

FEMA is committed to ensuring all participants have equal access regardless of disability status. If you require reasonable accommodation due to a disability to fully participate, please contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** caption as soon as possible.

**FOR FURTHER INFORMATION CONTACT:**

Brian Koper, Designated Federal Officer for the TMAC, FEMA, 400 C St. SW, Washington, DC 20472, 202–646–3085, [brian.koper@fema.dhs.gov](mailto:brian.koper@fema.dhs.gov). The TMAC website is: <https://www.fema.gov/flood-maps/guidance-partners/technical-mapping-advisory-council>.

**SUPPLEMENTARY INFORMATION:** Notice of this meeting is given under the *Federal Advisory Committee Act*, Public Law 117–286, 5 U.S.C. ch. 10.

In accordance with the *Biggert-Waters Flood Insurance Reform Act of 2012*, the TMAC makes recommendations to the FEMA Administrator on: (1) how to improve, in a cost-effective manner, the (a) accuracy, general quality, ease of use, and distribution and dissemination of flood insurance rate maps and risk data; and (b) performance metrics and milestones required to effectively and efficiently map flood risk areas in the United States; (2) mapping standards